Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a Series B financing round. The round was led by Yuecai Holdings’ biomedicine fund, with participation from Fuho Capital, Qianhai Liyuan Fund Management, Ningbo Jingxing Zhiyuan Venture Capital, and Ningbo Jinghang Intelligent Inspection Venture Capital Fund. The proceeds will be allocated towards clinical development, product pipeline expansion, talent team building, and other operational activities.
Company Background and Focus
Founded in 2017, Dartsbio Pharmaceuticals specializes in the research and development of novel antibody drugs targeting pain and cancer complications. The company, which operates in Shanghai and Zhengzhou, Henan, in addition to its headquarters in the Greater Bay Area, has initiated a Phase II clinical study for its long-acting painkiller. This funding round underscores Dartsbio’s commitment to advancing its innovative therapeutic pipeline.
Future Outlook
With the support from this Series B financing, Dartsbio Pharmaceuticals is poised to accelerate its clinical programs and expand its product offerings. The company’s focus on addressing significant unmet needs in pain management and oncology positions it well for future growth and innovation in the biopharmaceutical sector.-Fineline Info & Tech
